These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 30372907)

  • 41. [Modulation of the incretin effect in the treatment of diabetes].
    Vidal J
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():8-11. PubMed ID: 25437459
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
    Winkler G
    Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overview of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Patients with Type 2 Diabetes.
    Tran KL; Park YI; Pandya S; Muliyil NJ; Jensen BD; Huynh K; Nguyen QT
    Am Health Drug Benefits; 2017 Jun; 10(4):178-188. PubMed ID: 28794822
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incretin-based therapies: therapeutic rationale and pharmacological promise for type 2 diabetes.
    Wick A; Newlin K
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():623-30. PubMed ID: 19900193
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incretin-based therapies: where will we be 50 years from now?
    Meier JJ; Nauck MA
    Diabetologia; 2015 Aug; 58(8):1745-50. PubMed ID: 25994073
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 49. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.
    Muskiet MHA; Tonneijck L; Smits MM; van Baar MJB; Kramer MHH; Hoorn EJ; Joles JA; van Raalte DH
    Nat Rev Nephrol; 2017 Oct; 13(10):605-628. PubMed ID: 28869249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes.
    Martin CL
    Diabetes Educ; 2008; 34 Suppl 3():66S-72S. PubMed ID: 18525067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in micro- and nanotechnologies for the GLP-1-based therapy and imaging of pancreatic beta-cells.
    Moonschi FH; Hughes CB; Mussman GM; Fowlkes JL; Richards CI; Popescu I
    Acta Diabetol; 2018 May; 55(5):405-418. PubMed ID: 29264724
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
    Jódar E
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():12-7. PubMed ID: 25437460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
    Parkes DG; Mace KF; Trautmann ME
    Expert Opin Drug Discov; 2013 Feb; 8(2):219-44. PubMed ID: 23231438
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications.
    Nauck MA
    Am J Med; 2011 Jan; 124(1 Suppl):S3-18. PubMed ID: 21194578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells.
    Lee YS; Jun HS
    Metabolism; 2014 Jan; 63(1):9-19. PubMed ID: 24140094
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.
    Yap MKK; Misuan N
    Basic Clin Pharmacol Toxicol; 2019 May; 124(5):513-527. PubMed ID: 30417596
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Therapeutic strategies based on glucagon-like peptide 1.
    Deacon CF
    Diabetes; 2004 Sep; 53(9):2181-9. PubMed ID: 15331525
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.